Clinical Trial

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Study acronym: Carolyn-USA
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-30; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2026-02-03
Trial Details
NCT Number NCT07049055
Lead Sponsor Engeneic Pty Limited
Collaborators: Herbert Irving Comprehensive Cancer Center
Conditions Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Enrollment 144 participants
Start Date 2026-01-12
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-27